SLU-PP-332
Not medical advice. PepTutor summarizes fallible research and community signal for trained practitioners; some compounds are research-only, unapproved, controlled, jurisdiction-dependent, or labeled not for human consumption.
SLU-PP-332 is an experimental ERR agonist for users chasing fatty-acid oxidation, endurance, glucose uptake, stamina, and mitochondrial drive without appetite suppression or stimulant pressure.
No human safety trials exist; the practical red line is not routine peptide-style side effects, but unknown chronic, high-dose, proliferative, cardiac, and reproductive transfer risk from forcing ERR-driven metabolic programs.
SLU-PP-332 is an experimental ERR agonist for users chasing fatty-acid oxidation, endurance, glucose uptake, stamina, and mitochondrial drive without appetite suppression or stimulant pressure. The best current read is bullish but narrow: injectable SLU looks interesting for fat-loss and cardio-output stacks, while oral hype, high-dose escalation, and open-ended continuous use remain poor bets.
The evidence base is rodent and community-only. The common real-world failure mode is no effect from oral, weak, or mismatched product; the unresolved serious issues are chronic high-dose exposure, proliferative signaling, ERR/estrogen-receptor cross-talk, cardiac transfer risk, reproductive biology, and loss of effect with long continuous runs.
Its value is the unique mechanism: direct ERR activation that may raise the capacity to burn liberated fatty acids and sustain output, rather than GLP-1 appetite suppression, AMPK stress signaling, or PPAR-delta agonism. The value falls apart if diet/training or a lipolytic signal never releases substrate, the product is oral/inactive, or the user is a non-responder.
Reports are split but patterned. The strongest signal is positive for verified injectable SLU-PP-332, where responders describe better cardio output, fatty-acid oxidation, glucose uptake, stamina, and cleaner training feel; null reports cluster around oral products, uncertain sourcing, and users expecting appetite suppression.
Do not stack it blindly with Cardarine or other uncharacterized exercise mimetics; overlapping metabolic-reprogramming signals make risk attribution and cancer-marker interpretation messy.
Intro
SLU-PP-332 (CAS 303760-60-3) is a synthetic small-molecule pan-agonist of all three estrogen-related receptor isoforms: ERRα, ERRβ, and ERRγ.
It was developed at Washington University in St. Louis by the Bahaa Bhatt laboratory as a chemical probe for studying ERR biology and was not originally intended for human use. The compound gained significant community attention in 2022-2023 following a Nature Communications publication demonstrating that sedentary mice treated with SLU-PP-332 ran 70% longer and 45% farther than controls. This data was widely amplified in biohacking circles under the framing 'exercise in a pill.' Community adoption accelerated in 2024 as injectable-form reports displaced the earlier oral-capsule non-response pattern.
ERR receptors are orphan nuclear receptors — they have no established endogenous ligand but maintain constitutive transcriptional activity. ERRα and ERRγ are master regulators of the transcriptional programs activated by aerobic exercise: mitochondrial biogenesis, fatty acid oxidation (CPT1, HADHA), and oxidative phosphorylation. SLU-PP-332 agonizes all three ERR isoforms, with approximately 4-5x selectivity for ERRα over ERRβ in vitro, and upregulates the aerobic exercise gene program without requiring physical activity.
WADA has prohibited SLU-PP-332 as an exercise mimetic and metabolic modulator. There are no published human trials, registered clinical studies, or phase 1 safety data. Every effect described for humans in this article is derived from community self-experimentation. ERR technology dates to the year 2000 and predates the 2018 wave of peptide research; the Bhatt lab's 2022-2023 work brought it to mainstream community attention.
Critical framing: the strongest practical conclusion is bullish but bounded. Injectable SLU-PP-332 has a coherent mechanism, positive practitioner signal, and repeated reports of endurance, fat-oxidation, glucose-uptake, stamina, and mitochondrial benefits with relatively few acute side-effect complaints. The boundaries are product form, dose ceiling, substrate availability, duration, and chronic safety: oral products are usually treated as a miss, more dose is not automatically better, and long-term human risk remains unsettled.
Observed Effects
Primary effects in rodent models: running time +70% and running distance +45% versus sedentary controls (Nature Communications, Bhatt lab 2022).
Improved insulin sensitivity, enhanced glucose uptake (GLUT4 upregulation), reduced fat mass, and improved metabolic syndrome markers in multiple mouse model studies.
Community-reported effects (injectable route): improved exercise capacity perceived from first injection in responsive users; enhanced endurance and stamina; improved fatty acid oxidation during fat loss phases; better glucose control metrics in users combining with GLP-1 agonists; reduced oxidative stress and improved mitochondrial ATP generation. Energy improvement typically diminishes toward baseline at approximately 100 days of continuous use.
Critical caveat — response is highly variable. A significant proportion of users report no subjective response, particularly at low doses or with oral forms. Bimodal response pattern observed across community sources with no clear predictor. Hypothesized basis: individual ERR receptor architecture variants, including possible N-terminal truncation polymorphisms. Standard blood work captures nothing from SLU-PP-332 use — no visible changes to routine lab panels. Mitochondrial complex efficiency (Mito Saliva Test) is the only direct objective consumer metric.
No serious adverse events (hospitalization, cardiac events, organ damage) have been documented in accessible community sources as of May 2026. However, this absence of evidence should not be interpreted as safety confirmation given the small and self-selected user base.
Field Reports
Positive reports: injectable users describe improved glucose control and cardio output, with several accounts explicitly contrasting active injectable use against ineffective oral use.
One structured 60-day self-experiment included Bod Pod body composition testing and bloodwork before and after, which makes it more useful than pure subjective impression. A long-duration biohacker account reported 9 months of continuous use for fat oxidation and glucose control benefits, still taking it daily at publication. Multiple community writeups report improved fat-loss support and muscle preservation during calorie restriction.
Negative and neutral reports: multiple users report zero response on oral SLU-PP-332 at 500mcg twice daily for full cycles — these are the primary basis for community rejection of the oral route. One user reported no subjective difference at week 8 on a stack of oral SLU-PP-332 plus retatrutide plus growth hormone, though polypharmacy makes attribution impossible. High-dose users report energy burnout pattern with earlier energy decline than low-dose users. High-dose adverse experiences exist in the packet, but the specific symptom list still needs direct-identity verification before publication.
Response pattern: energy improvement during cycle, gradual return to pre-cycle baseline levels after cessation (not a below-baseline crash in most reports). Energy levels diminish toward baseline at approximately 100 days of continuous use.
Community Consensus
Community adoption spiked in 2023-2024 following media amplification of the Bhatt lab Nature Communications mouse study.
Primary adoption vectors included podcast, bodybuilding, GLP-1, and longevity coverage, then injectable forms became the center of discussion after oral capsule non-response became widely documented.
Primary community framing is 'exercise in a pill,' but the mature consensus is more useful: SLU-PP-332 is a mitochondrial/fatty-acid-oxidation tool, not a replacement for training or a guarantee of fat loss. It is consistently discussed alongside MOTS-c, SS-31, Cardarine, mirabegron, methylene blue, GLP-1 agonists, and stimulant/lipolytic fat-loss tools because the practical question is usually whether the user needs more substrate release, more mitochondrial utilization, or both.
The priority practitioner take is bullish on the compound's upside. Injectable responders can feel endurance and cardio-output changes quickly, the mechanism makes sense for cuts and metabolic-health phases, and the recurring benefits cluster around fatty-acid oxidation, glucose uptake, mitochondrial biogenesis/respiration, stamina, and fat-loss-phase support. Cardarine, mirabegron, methylene blue, carnitine, and clenbuterol-type pairings are viewed as mechanistically synergistic because they either increase substrate release or improve mitochondrial handling of that substrate.
The bullish take still has boundaries: oral SLU-PP-332 is treated as ineffective, 1mg/day is the practical ceiling for most users, high-dose escalation is doubted, and human duration, optimal dose, product form, and chronic effects are unresolved. This is why the final read is 'worth attention if run intelligently,' not 'casual peptide.'
Community debates: oral vs injectable bioavailability (now largely resolved — oral is considered ineffective); dose ceiling; confusion with MOTS-c or other mitochondrial peptides among newer users; effect attribution difficulty in polypharmacy contexts, especially GLP-1 or retatrutide stacks.
Community classification: early adopter / research chemical tier. The balanced consensus is not 'too dangerous to discuss' and not 'low-risk peptide'; it is a real-mechanism compound with unusually positive practitioner signal, strong route/product-quality dependency, and enough unresolved chronic-safety questions that experienced users treat it as an advanced but worthwhile experiment.
Risks & Monitoring
Unknown long-term safety profile is the primary concern — no human safety trials exist and high-dose long-term risk is genuinely uncharacterized.
The acute community texture is relatively clean compared with stimulants or androgens, but that does not answer the chronic ERR question.
Cancer marker elevation: experienced community safety protocols flag CEA, PSA in males, and CA-125 in females as a practical monitoring gate. The mechanism — upregulation of cellular metabolic programs — creates theoretical concern for accelerating pre-existing proliferative processes. No community reports of malignancy are established, but sample size is small and follow-up duration is short.
ERR/ER cross-talk risk: ERRα shares approximately 70% LBD homology with ERα and partial target gene overlap. Theoretical cross-interaction between ERR signaling and ER signaling exists; certainty is low and the practical position is 'time will tell.' ERRα activation in ocular tissue may have estrogen-receptor-like effects via shared gene networks. No gynecomastia or estrogen-related side effects reported in community.
Energy decline: energy level improvement diminishes toward baseline at approximately 100 days of continuous use. High-dose users (5–10mg/day) report earlier burnout pattern and diminishing metabolic response. On cessation, return to pre-cycle baseline is the most common reported pattern.
PDK4 upregulation concern: chronically elevated fatty acid oxidation upregulates PDK4, which inhibits pyruvate dehydrogenase. This may impair glucose oxidation flexibility over time. Not documented clinically; theoretical based on FAO biochemistry.
High-dose adverse experience exists in the community packet, but the accessible excerpts do not give enough detail to publish a specific side-effect list. Treat high-dose escalation as evidence-needed rather than a cleared dose-response lane.
For Women
Monitoring Panels
REQUIRED is a real safety gate. RECOMMENDED is the prudent default. OPTIONAL covers symptoms, risk factors, or tighter tracking.
A high-caution safety gate in experienced community protocols, not a clinically validated SLU-PP-332 requirement. ERR-driven upregulation of cellular metabolic programs creates theoretical concern for accelerating proliferative processes. Baseline is most relevant for cancer history, high-caution users, Cardarine co-use, or longer cycles.
Mid-cycle check at 4–6 weeks to identify any unexpected elevation before completing a full course when following the high-caution cancer-marker monitoring approach.
SLU-PP-332 modulates glucose uptake and insulin sensitivity. Baseline allows detection of changes, particularly important in users with pre-diabetes.
Chronic upregulation of fatty acid oxidation may alter circulating lipid dynamics. Baseline lipids allow tracking of trajectory.
ERRα is highly expressed in liver and drives hepatic fatty acid oxidation. Liver enzyme baseline warranted given unknown hepatic effects at community doses.
Only direct consumer measurement of mitochondrial complex efficiency. Pre/post testing documents whether SLU-PP-332 is producing objective mitochondrial response, since standard blood work cannot capture this.
Compare to baseline Mito Saliva Test to quantify actual mitochondrial change from the cycle.
Avoid With
Do not combine SLU-PP-332 with the following. Sorted highest-severity first.
Why:Methylene blue inhibits MAO-A; combination with serotonergic drugs risks serotonin syndrome
What to do:This is a contraindication for the SLU-PP-332 + Methylene Blue combination, not for SLU-PP-332 alone. If on serotonergic medications, skip methylene blue from the stack.
Why:Both compounds upregulate cellular metabolic programs; additive theoretical oncogenic concern from Cardarine's rodent carcinogenicity history
What to do:Not a hard contraindication — community widely uses this combination — but baseline cancer markers (CEA, PSA/CA-125) and a mid-cycle check are the prudent safety-gate approach in this stack.
Why:SLU-PP-332 has no human safety data; stacking with other compounds with unknown profiles multiplies unknowns and makes attribution impossible
What to do:Most community users run SLU-PP-332 in a context of 20-50 concurrent compounds. Risk attribution and safety monitoring become extremely difficult.
Protocols By Goal
Fat loss: reports commonly pair SLU-PP-332 0.5-1mg/day subQ with caloric restriction. The point is fatty-acid utilization, so the protocol only makes sense when diet, training, or a separate lipolytic signal is releasing substrate to oxidize. Clenbuterol or mirabegron are heavier lipolysis options sometimes discussed in the same lane, but they add cardiovascular, prescription, and interaction burden; they should not be treated as default beginner stack pieces. Reported cycles commonly run 6-8 weeks with cancer-marker monitoring only in high-caution protocols and body composition checks at weeks 4 and 8.
Metabolic health: reports commonly use SLU-PP-332 around 0.5-1mg/day subQ alongside structured exercise (resistance + aerobic) to synergize with mitochondrial biogenesis signaling. Methylene blue appears in some electron-transport-chain optimization stacks only after medication conflicts are cleared. Fasting glucose, HbA1c, and optional mitochondrial testing are the more mechanism-aligned monitoring endpoints.
Endurance enhancement: reports commonly use SLU-PP-332 around 0.5-1mg/day subQ before a peak training phase. Cardarine is the most discussed dual PPARδ + ERR pathway stack, but it turns the protocol into a higher-caution cancer-marker experiment because Cardarine brings its own rodent carcinogenicity baggage. WADA-prohibited — not suitable for tested athletes. Performance metrics (VO2max proxy, time trials, power output) are the appropriate monitoring endpoints.
Dosing Details
Injectable subcutaneous use is the dominant reported route. Oral capsule non-response is widely documented across multiple community sources, and community consensus is that oral bioavailability is negligible.
Standard reported dosing for fat loss or metabolic enhancement clusters around 0.5-1mg per day subcutaneous, usually once daily or split across two exposures, with 4-8 week cycles and an equal or longer off-period. This is observed practice, not a clinically validated dosing schedule.
Dose ceiling: structured community analysis documents that users escalating to 5-10mg/day report diminishing metabolic response compared to lower doses — a potential inverse dose-response or ceiling phenomenon. Most community educators converge on 1mg/day as the effective practical ceiling.
Aggressive reports reach 1-3mg/day subcutaneous with divided dosing. Half-life is not formally characterized but inferred as short from BID protocol preference. Higher doses have not demonstrated superior outcomes in community reports and increase the unknowns around long-term risk.
Human equivalent dose uncertainty: the mouse study used doses that when scaled by body weight suggest human equivalents far above community doses. Whether community doses of 0.5-3mg/day produce pharmacologically meaningful ERR agonism in humans at plasma concentrations achieved is unresolved.
For GLP-1 stacks (semaglutide, tirzepatide, retatrutide), reports commonly describe 0.5-1mg/day subcutaneous. Interaction with GLP-1 agonists is not characterized; attribution of specific fat loss effects becomes difficult in this combination. Community reports generally describe positive additive experience.
Stacks & Alternatives
Dual activation: ERR pathway via SLU-PP-332 (mitochondrial biogenesis) + PPARδ pathway via cardarine (fatty acid oxidation, fiber type switching). Overlapping target gene networks create additive FAO upregulation. This is the most frequently cited synergy stack, but it is not casual because Cardarine has rodent carcinogenicity data at high doses — monitor cancer markers if using this lane.
Mechanistically complementary: SLU-PP-332 upregulates mitochondrial biogenesis (more mitochondria); methylene blue donates electrons to complex IV, optimizing electron transport chain efficiency (better mitochondria). Addresses quantity and quality of mitochondrial function simultaneously.
β3-adrenergic agonist stimulates lipolysis in brown adipose tissue and activates UCP1. SLU-PP-332 enhances capacity to oxidize the liberated fatty acids. Dual mechanism: fat mobilization (mirabegron) + fat burning (SLU-PP-332). Described as 'whopping dual fatty acid oxidation' by community.
Clenbuterol drives lipolysis via β2-adrenergic stimulation; SLU-PP-332 enhances mitochondrial fatty acid oxidation capacity. Lipolysis + oxidation stack addresses both fat mobilization and utilization steps.
Complementary mitochondrial mechanisms: MOTS-c (mitochondrial-derived peptide) activates AMPK and modulates nuclear gene expression; SLU-PP-332 activates ERR-dependent transcriptional programs. Both are mitochondrial health compounds with non-overlapping signaling pathways.
GLP-1 agonists drive caloric deficit and fat mobilization via appetite suppression and gastric emptying delay; SLU-PP-332 enhances capacity to oxidize mobilized fat. Fat mobilization + fat burning axis.
Alternatives
Stack Cost
SLU-PP-332 consumes uncertainty capacity: it adds research-chemical, route/sourcing, chronic-safety, and same-lane exercise-mimetic burden even though it does not add HPG suppression or classic stimulant strain.
Broad ERR activation is intended to upregulate cellular metabolic programs; experienced community safety protocols repeatedly point to CEA, PSA, and CA-125 tracking because proliferative-risk transfer is unknown in humans.
Community use is dominated by gray-market products with route and solvent ambiguity. Oral products often produce null results, while injectable claims raise solubility and vehicle questions.
Ordinary use does not have validated SLU-specific safety labs, but the uncertainty itself creates a monitoring burden: cancer markers when using the high-caution protocol, glucose/A1c, lipids, liver enzymes, and optional mitochondrial-function testing.
The compound is often stacked with Cardarine, methylene blue, GLP-1s, clenbuterol, mirabegron, or other metabolic tools, which makes attribution and overlapping risk management harder.
- ·Keep it out of kitchen-sink research-chemical stacks; run fewer variables so response and adverse signals can be attributed.
- ·If Cardarine is used, treat the stack as a cancer-marker-monitored experiment rather than a casual endurance stack.
- ·Do not count SLU-PP-332 as a substitute for training; its animal data does not reproduce the full hormonal, connective-tissue, and neurotrophic cascade of exercise.
- ·Avoid pregnancy/fertility contexts until reproductive safety is established.
- ·Baseline and mid-cycle cancer-marker decision point if following the high-caution community safety practice.
- ·Glucose/A1c, lipid, and liver-enzyme baseline if using it for metabolic goals.
- ·Identity verification, correct formulation, and careful route documentation.
- ·Cycle breaks because continuous-use durability and long-term safety are unknown.
The ordinary-use problem is not injection hassle; it is that humans do not yet have safety trials, pharmacokinetics, validated dosing, or clear product-form standards. A beginner cannot easily know whether no effect means non-response, bad product, wrong route, or underdosing.
- ·Pregnant, trying to conceive, or breastfeeding.
- ·Personal cancer history or unexplained cancer-marker elevation.
- ·Cardiac hypertrophy, arrhythmia, unexplained tachycardia, or uncontrolled hypertension.
- ·Already running multiple uncharacterized metabolic research chemicals.
No HPG suppression or withdrawal pattern is established; stopping mainly removes the hoped-for endurance/metabolic effect.
- ·benefit loss
- ·energy or cardio-output return toward baseline
- ·loss of glucose/fat-oxidation support if the user was a responder
Do not escalate blindly. Re-check route, vehicle, COA credibility, and whether the product is oral/injectable before increasing dose.
Run fewer variables and keep body weight, training output, glucose, sleep, and side-effect notes separate.
Stop, pull relevant labs, and treat abnormal cancer/cardiac signals as a hard escalation point rather than a normal adjustment period.
The intended biology upregulates metabolic programs and the human proliferative-risk profile is unknown.
ERR signaling intersects with reproductive and placental biology, and no human reproductive safety data exists.
ERR-gamma and mitochondrial-output biology make cardiac transfer risk a evidence-needed area, not a cleared lane.
The more metabolic variables are active, the less interpretable both benefit and adverse signals become.
Practical Setup
Route: injectable subcutaneous use is the main reported route. Oral bioavailability is considered negligible by community consensus, with multiple documented zero-response cases on oral capsules.
Dose: 1mg/day is the practical community ceiling. Escalating to 5-10mg/day produces diminishing returns or burnout in structured community analysis. Conservative first-cycle reports often begin below that ceiling to assess response before committing to a full cycle.
Cycle: 4-8 weeks with equal or longer off-periods. Effects diminish toward baseline at 100 days; plan accordingly. Multiple cycles appear to retain effect on re-introduction.
Diet: SLU-PP-332 improves fatty acid utilization but requires liberated fatty acids as substrate. Works best in caloric deficit, with structured cardio, or in a stack where lipolysis is already happening. Excess caloric intake limits observable fat loss outcomes even with enhanced oxidation capacity. The compound addresses the utilization bottleneck (mitochondrial oxidation capacity), not the release step (lipolysis).
Exercise: high-intensity exercise (Wingate protocol) may produce comparable mitochondrial biogenesis. Combining structured exercise with SLU-PP-332 is expected to be additive. The compound is used by people who want both the training signal and the ERR signal, not because it recreates every benefit of training.
Monitoring: standard blood work does not capture the primary mechanism — no routine panel markers reliably change with SLU-PP-332 use. Cancer marker monitoring is the main safety-gate approach in experienced community protocols. Mito Saliva Test (US only) is the only direct objective consumer measurement of mitochondrial complex efficiency, recommended pre and post cycle when available.
Biomarkers to track: cancer markers (CEA, PSA or CA-125) if following the high-caution protocol; fasting glucose and HbA1c (mechanism-aligned); liver enzymes AST/ALT (ERRα hepatic expression); lipid panel (chronic FAO effects); Mito Saliva Test optional but useful for objective response documentation.
Mechanism Deep Dive
ERR receptor biology: SLU-PP-332 is a synthetic small-molecule pan-agonist of the estrogen-related receptor family (ERRα, ERRβ, ERRγ).
These are nuclear receptors in the same superfamily as classical estrogen receptors (ERα/ERβ) but structurally and functionally distinct. ERRs are orphan receptors — they have no established endogenous ligand yet maintain constitutive transcriptional activity via their AF-2 helix conformation. Cholesterol acts as a natural ERR agonist in some contexts. Classical estrogens (estradiol, estrone, phytoestrogens) do not bind ERR receptors.
Molecular mechanism: ERRα's ligand binding domain shares approximately 70% sequence homology with ERα's LBD but adopts a constitutively active conformation. SLU-PP-332 further stabilizes this active conformation, potentiating transcriptional output. SLU-PP-332 has approximately 4–5x selectivity for ERRα over ERRβ in vitro, with low-moderate ERRβ affinity and meaningful ERRγ activity (pan-agonism). ERRγ is predominantly mitochondrially localized and regulates electron transport chain complex efficiency; ERRα is more nuclear and transcriptional.
Downstream gene programs: ERRα/γ activation drives mitochondrial biogenesis (TFAM, NRF1, PGC1α co-activation), fatty acid oxidation (CPT1, HADHA, ACSL1), oxidative phosphorylation gene expression, glucose transport (GLUT4 upregulation), and fiber type switching toward oxidative slow-twitch muscle. PGC1alpha coactivator forms physical complexes with ERR isoforms, amplifying downstream signaling. All three isoforms must be stimulated for full mitochondrial benefit — pan-agonism is considered superior to selective isoform activation.
Tissue distribution: ERRα is highly expressed in skeletal muscle (primary exercise effect), liver (hepatic fatty acid oxidation and glucose output), brown adipose tissue (thermogenesis), white adipose tissue (lipolysis/oxidation), and heart (cardiac energy metabolism).
Relationship to exercise: SLU-PP-332 activates the same transcriptional programs induced by acute aerobic exercise, bypassing the exercise energy stress signal (AMP/ATP ratio change that activates AMPK). This mechanistic distinction from AICAR (AMPK activator) and cardarine (PPARδ agonist) positions SLU-PP-332 as a direct transcriptional mimetic of exercise's nuclear receptor outcomes, without the upstream energy stress signaling.
ERR/ER cross-talk: theoretical cross-interaction between ERR and classical estrogen receptor signaling exists via partial target gene network overlap. ERRα activation in ocular tissue may have ERα-like effects. Certainty is low (0.5); no estrogen-related adverse effects reported in community. Post-translational regulation of ERR (phosphorylation, acetylation, sumoylation) may contribute to the highly variable individual response pattern observed in community use.
PDK4 concern: chronically elevated fatty acid oxidation upregulates PDK4 (pyruvate dehydrogenase kinase 4), which phosphorylates and inactivates pyruvate dehydrogenase. This may impair metabolic flexibility (glucose-to-fat oxidation switching) over time with sustained SLU-PP-332 use.
Evidence Index
Quantitative claims trace to these source studies. Population, dose, and study type matter — claims from HIV-lipodystrophy trials don't transfer cleanly to healthy adults; data from supraphysiologic doses doesn't apply at TRT.
Running time +70% in sedentary mice versus controls
Nature Communications study (Bhatt lab, Washington University). Primary community adoption driver. Direct extrapolation to humans is not valid — mouse-to-human pharmacokinetic scaling for this compound class is unresolved.
Running distance +45% in sedentary mice versus controls
Complementary endpoint to ep_001. Same Bhatt lab Nature Communications study. Running time and running distance improvements reported together.
Improved insulin sensitivity, reduced fat mass, and metabolic syndrome marker improvement
Consistent finding across multiple mouse model studies. Human translation requires clinical trial data not currently available.
Exercise capacity improvement, fat loss support, and glucose control improvement in community users
Community self-reports 2024–2026. Selection bias toward positive reporting, small sample, no controls, no blinding. Oral route reports show near-universal non-response.
Oral SLU-PP-332 at 500mcg twice daily produced no subjective response in multiple community reports
Supports the article's route warning only. It does not establish injectable pharmacokinetics or prove every oral formulation is inactive.
Users escalating to 5–10mg/day report diminishing metabolic response or burnout compared with lower doses
Dose-ceiling signal is community-derived and vulnerable to product-quality confounding. It should guide caution, not be treated as validated pharmacology.
Energy improvement diminishes toward baseline at approximately 100 days of continuous use
Useful for cycle-duration caution. It is not a controlled tolerance study and should not be generalized to all responders.
Not medical advice. PepTutor summarizes fallible research and community signal for trained practitioners; some compounds are research-only, unapproved, controlled, jurisdiction-dependent, or labeled not for human consumption.